Physician profile
Bryan M White
NPI 1386715837
$3,741.18
in general payments reported to CMS, 2019-2025
27 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $13.20 · 2021: $82.11 · 2022: $196 · 2023: $335 · 2024: $1,332 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,115.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $783.64 | 2024-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $483.73 | 2021-2025 | Farxiga, Lokelma, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $325.09 | 2019-2025 | Lifevest |
| Abbott Laboratories | $274.56 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Pfizer INC. | $234.10 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.30 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $229.33 | 2024-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $166.03 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $154.52 | 2024-2025 | Verquvo, Capvaxive |
| Cardiovascular Systems INC. | $129.65 | 2019-2023 | Diamondback Coronary |
| Philips North America LLC | $129.20 | 2022-2024 | (Ck4) Mcot |
| Cvrx, INC. | $125.00 | 2019 | |
| Amgen INC. | $96.83 | 2024-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $60.87 | 2024-2025 | |
| Medtronic Vascular, INC. | $54.80 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $36.84 | 2024 | Xarelto |
| Baxter Healthcare | $29.84 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Acutus Medical, INC. | $22.70 | 2022 | |
| Inspire Medical Systems, INC. | $22.19 | 2025 | Inspire |
| La Jolla Pharmaceutical Company | $21.58 | 2021 | |
| Bridgebio Pharma, INC. | $20.97 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $19.72 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $19.27 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $19.26 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $18.18 | 2024 | |
| Irhythm Technologies, INC. | $16.43 | 2023 | Zio Xt Patch |
| Vifor Pharma, INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.